Aurinia Pharmaceuticals (FRA:IKAP) Total Assets : €467.0 Mil (As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is Aurinia Pharmaceuticals Total Assets?

Aurinia Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2025 was €467.0 Mil.

During the past 12 months, Aurinia Pharmaceuticals's average Total Assets Growth Rate was -2.40% per year. During the past 3 years, the average Total Assets Growth Rate was 35.50% per year. During the past 5 years, the average Total Assets Growth Rate was 54.10% per year. During the past 10 years, the average Total Assets Growth Rate was 31.30% per year.

During the past 13 years, Aurinia Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 85.00%. The lowest was -27.50%. And the median was 23.45%.

Total Assets is connected with ROA %. Aurinia Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2025 was 17.40%. Total Assets is also linked to Revenue through Asset Turnover. Aurinia Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2025 was 0.12.

Aurinia Pharmaceuticals Total Assets Historical Data

The historical data trend for Aurinia Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Total Assets Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

381.13

480.88

444.49

502.57

525.87

Aurinia Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Assets	Get a 7-Day Free Trial															475.30	486.36	494.97	525.87	466.99

Aurinia Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aurinia Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	360.491	+	165.374
	=	525.9

Aurinia Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2025 )	+	Total Liabilities (Q: Mar. 2025 )
	=	323.926	+	143.06
	=	467.0

Aurinia Pharmaceuticals (FRA:IKAP) Total Assets Explanation

Total Assets is connected with ROA %.

Aurinia Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %	=	Net Income (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	86.372	/	( (525.866	+	466.986)	/ 2 )
	=	86.372	/	496.426
	=	17.40 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aurinia Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2025 is

	Asset Turnover
=	Revenue (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
=	57.78	/	( (525.866	+	466.986)	/ 2 )
=	57.78	/	496.426
=	0.12

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aurinia Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (FRA:IKAP) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

AUPH:USA IKAP:Germany

Address

14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Headlines

No Headlines